U.S. markets open in 4 hours 58 minutes
  • S&P Futures

    4,327.25
    +9.50 (+0.22%)
     
  • Dow Futures

    34,055.00
    +12.00 (+0.04%)
     
  • Nasdaq Futures

    14,086.00
    +99.25 (+0.71%)
     
  • Russell 2000 Futures

    1,920.30
    -8.00 (-0.41%)
     
  • Crude Oil

    86.96
    +0.35 (+0.40%)
     
  • Gold

    1,791.30
    -3.70 (-0.21%)
     
  • Silver

    22.51
    -0.16 (-0.71%)
     
  • EUR/USD

    1.1136
    -0.0011 (-0.10%)
     
  • 10-Yr Bond

    1.8070
    0.0000 (0.00%)
     
  • Vix

    30.16
    -1.80 (-5.63%)
     
  • GBP/USD

    1.3371
    -0.0010 (-0.07%)
     
  • USD/JPY

    115.5170
    +0.2150 (+0.19%)
     
  • BTC-USD

    36,710.81
    +165.25 (+0.45%)
     
  • CMC Crypto 200

    832.60
    +13.10 (+1.60%)
     
  • FTSE 100

    7,501.11
    -53.20 (-0.70%)
     
  • Nikkei 225

    26,717.34
    +547.04 (+2.09%)
     

3 Beaten-Down Biotech Stocks -- Are They Bargains Now?

·4 min read
3 Beaten-Down Biotech Stocks -- Are They Bargains Now?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • EDIT
  • RETA
  • ADGI

The benchmark SPDR S&P Biotech ETF (NYSEMKT: XBI) recently started to recover, but it's still down more than 33% from a peak it reached this February. Editas Medicine (NASDAQ: EDIT) shares are down a whopping 54% over the past three months. It's been falling harder than most biotech stocks this year thanks to disappointing clinical trial results for its lead candidate, EDIT-101.